Bobby Allyn
Kalshi and Polymarket say allowing people to bet on the outcomes of clinical trials and FDA drug approvals provides valuable information about drug development. But researchers warn the bets could incentivize insider trading and interfere with the integrity of the process. Fred Tanneau/AFP via Getty Images hide caption
As a soon-to-be seventh grader, Joshua Pederson's son is not exactly brimming with enthusiasm when he talks about the upcoming school year.
"The thing I'm looking forward to most in seventh grade is lunch, and the thing I'm looking forward to least is everything else," said the 12-year-old.
Art is his passion, but he doesn't take classes. He likes teaching himself.
